

Attorney Docket No.: 3469.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rasmussen et al.

Serial No.: 09/189,028

Group Art Unit: 1652

Filed: November 10, 1998

Examiner: L. Hobbs

For: A Cellulase Preparation Comprising An Endoglucanase Enzyme

SUBMISSION CONCERNING SEQUENCE LISTING

Box Sequence
Assistant Commissioner for Patents
Washington, DC 20231

official
LJA 7/31/00

Sir:

Applicants mailed a Sequence Listing for this application no April 24, 2000. The computer-readable form in this application is identical with that filed in application no. 08/369,423, the benefit of which is claimed under 35 U.S.C. 120. In accordance with 37 CFR 1.821(e), please use the computer readable form filed on October 22, 1996 as corrected by the Office Action of August 17, 1998 in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. The content of the "SEQUENCE LISTING" filed in the present application on April 24, 2000 and of the diskette filed in the parent application is the same.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: July 31, 2000

Elias J. Lambiris
Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

Attorney Docket No.: 3469.224-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rasmussen et al.

Serial No.: 09/189,028

Group Art Unit: 1652

Filed: November 10, 1998

Examiner: Hobbs, L.

For: A Cellulase Preparation Comprising An Endoglucanase Enzyme

CERTIFICATE OF FACSIMILE TRANSMISSION

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Submission concerning Sequence Listing

was sent to the United States Patent Office by telefax to the attention of Examiner Hobbs, L., fax number (703) 305-0854.

Respectfully submitted,

Date: July 31, 2000



Elias J. Lambiris, Esq.
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123